The OAK study investigating the efficacy of atezolizumab (an anti-PD-L1 antibody) showed that the treatment of PD-L1-negative NSCLC with atezolizumab led to improved survival rates compared to docetaxel treatment [10]. Here, CD274 is linked to non-small cell lung carcinoma.